About
Michael joined Polyneuron in January 2018 as Chief Business Officer. He brings to Polyneuron more than fifteen years’ experience in the life science industry. Previously, he was founder, board member and CSO of GlycoVaxyn, a vaccine development company that was acquired by GSK in 2015 and which valued the company at $212 million. Michael co-founded GlycoVaxyn in 2004 as a Spin-off company from the Swiss Federal Institute of Technology Zurich (ETHZ). Michael holds a M.Sc. in biochemistry and completed his Ph.D. and post-doctoral fellowship in microbiology at ETHZ. He is co-founder and member of the board of directors of Limmatech Biologics, Inura Medical and chairman of the board of Inositec. He is the author of several publications in international scientific journals, including Science and PNAS, as well as inventor of various patent applications.
Position in the VCSift Database
- • 51 investors hold the Chief Business Officer role in VCSift. Michael Wacker is one of them.
- • 779 investors are based in Zürich, Zurich, Switzerland.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Location
- Zürich, Switzerland
Contact Information
Find more investors like Michael
Search Investors